Logo image of ELABS.OL

ELLIPTIC LABORATORIES ASA (ELABS.OL) Stock Fundamental Analysis

OSL:ELABS - Euronext Oslo - NO0010722283 - Common Stock - Currency: NOK

12.72  +0.04 (+0.32%)

Fundamental Rating

4

Overall ELABS gets a fundamental rating of 4 out of 10. We evaluated ELABS against 102 industry peers in the Software industry. The financial health of ELABS is average, but there are quite some concerns on its profitability. ELABS is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ELABS had negative earnings in the past year.
ELABS had a negative operating cash flow in the past year.
In the past 5 years ELABS reported 4 times negative net income.
In the past 5 years ELABS always reported negative operating cash flow.
ELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of 2.48%, ELABS perfoms like the industry average, outperforming 55.88% of the companies in the same industry.
ELABS has a Return On Equity (2.75%) which is comparable to the rest of the industry.
With a Return On Invested Capital value of 1.32%, ELABS perfoms like the industry average, outperforming 51.96% of the companies in the same industry.
Industry RankSector Rank
ROA 2.48%
ROE 2.75%
ROIC 1.32%
ROA(3y)-5.97%
ROA(5y)-5.33%
ROE(3y)-6.62%
ROE(5y)-5.96%
ROIC(3y)N/A
ROIC(5y)N/A
ELABS.OL Yearly ROA, ROE, ROICELABS.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

The Profit Margin of ELABS (6.79%) is better than 62.75% of its industry peers.
Looking at the Operating Margin, with a value of 4.35%, ELABS is in line with its industry, outperforming 54.90% of the companies in the same industry.
Industry RankSector Rank
OM 4.35%
PM (TTM) 6.79%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELABS.OL Yearly Profit, Operating, Gross MarginsELABS.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

5

2. Health

2.1 Basic Checks

ELABS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ELABS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ELABS has more shares outstanding
Compared to 1 year ago, ELABS has an improved debt to assets ratio.
ELABS.OL Yearly Shares OutstandingELABS.OL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ELABS.OL Yearly Total Debt VS Total AssetsELABS.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

A Debt/Equity ratio of 0.03 indicates that ELABS is not too dependend on debt financing.
ELABS's Debt to Equity ratio of 0.03 is amongst the best of the industry. ELABS outperforms 82.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z N/A
ROIC/WACC0.15
WACC9.05%
ELABS.OL Yearly LT Debt VS Equity VS FCFELABS.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ELABS has a Current Ratio of 7.83. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.
ELABS's Current ratio of 7.83 is amongst the best of the industry. ELABS outperforms 95.10% of its industry peers.
A Quick Ratio of 7.83 indicates that ELABS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.83, ELABS belongs to the top of the industry, outperforming 95.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.83
Quick Ratio 7.83
ELABS.OL Yearly Current Assets VS Current LiabilitesELABS.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 91.67% over the past year.
The Revenue has grown by 93.08% in the past year. This is a very strong growth!
Measured over the past years, ELABS shows a very strong growth in Revenue. The Revenue has been growing by 28.29% on average per year.
EPS 1Y (TTM)91.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)93.08%
Revenue growth 3Y34.19%
Revenue growth 5Y28.29%
Sales Q2Q%19.73%

3.2 Future

ELABS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 195.30% yearly.
ELABS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 62.13% yearly.
EPS Next Y801.25%
EPS Next 2Y309.11%
EPS Next 3Y195.3%
EPS Next 5YN/A
Revenue Next Year97.78%
Revenue Next 2Y75.1%
Revenue Next 3Y62.13%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ELABS.OL Yearly Revenue VS EstimatesELABS.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ELABS.OL Yearly EPS VS EstimatesELABS.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5 2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELABS. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 9.50, the valuation of ELABS can be described as reasonable.
91.18% of the companies in the same industry are more expensive than ELABS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.19. ELABS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 9.5
ELABS.OL Price Earnings VS Forward Price EarningsELABS.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600

4.2 Price Multiples

ELABS's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 46.6
ELABS.OL Per share dataELABS.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ELABS's earnings are expected to grow with 195.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y309.11%
EPS Next 3Y195.3%

More info and screens

0

5. Dividend

5.1 Amount

ELABS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELLIPTIC LABORATORIES ASA

OSL:ELABS (6/20/2025, 4:19:56 PM)

12.72

+0.04 (+0.32%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)05-22 2025-05-22/bmo
Earnings (Next)N/A N/A
Inst Owners35.11%
Inst Owner ChangeN/A
Ins Owners8.64%
Ins Owner ChangeN/A
Market Cap1.34B
Analysts84
Price Target19.38 (52.36%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.39%
Min Revenue beat(2)-12.73%
Max Revenue beat(2)13.5%
Revenue beat(4)1
Avg Revenue beat(4)-6.29%
Min Revenue beat(4)-19.76%
Max Revenue beat(4)13.5%
Revenue beat(8)2
Avg Revenue beat(8)-22.24%
Revenue beat(12)3
Avg Revenue beat(12)-16.12%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)4.48%
Revenue NQ rev (1m)-2.54%
Revenue NQ rev (3m)-2.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.5
P/S 10.15
P/FCF N/A
P/OCF N/A
P/B 4.12
P/tB 5.17
EV/EBITDA 46.6
EPS(TTM)-0.02
EYN/A
EPS(NY)1.34
Fwd EY10.53%
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS1.25
BVpS3.09
TBVpS2.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.48%
ROE 2.75%
ROCE 1.71%
ROIC 1.32%
ROICexc 1.69%
ROICexgc 2.26%
OM 4.35%
PM (TTM) 6.79%
GM N/A
FCFM N/A
ROA(3y)-5.97%
ROA(5y)-5.33%
ROE(3y)-6.62%
ROE(5y)-5.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.39
Cap/Depr 139.53%
Cap/Sales 23.12%
Interest Coverage 3.13
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.83
Quick Ratio 7.83
Altman-Z N/A
F-Score6
WACC9.05%
ROIC/WACC0.15
Cap/Depr(3y)167.84%
Cap/Depr(5y)198.62%
Cap/Sales(3y)35.14%
Cap/Sales(5y)37.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next Y801.25%
EPS Next 2Y309.11%
EPS Next 3Y195.3%
EPS Next 5YN/A
Revenue 1Y (TTM)93.08%
Revenue growth 3Y34.19%
Revenue growth 5Y28.29%
Sales Q2Q%19.73%
Revenue Next Year97.78%
Revenue Next 2Y75.1%
Revenue Next 3Y62.13%
Revenue Next 5YN/A
EBIT growth 1Y111.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17528.6%
EBIT Next 3Y678.6%
EBIT Next 5YN/A
FCF growth 1Y35.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.16%
OCF growth 3YN/A
OCF growth 5YN/A